CNS Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- CNS Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CNSP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001729427
Board of directors
-
Amy Mahery · DirectorSince 2024
-
Andrzej Andraczke · DirectorSince 2023
-
Bettina M. Cockroft · DirectorSince 2023
-
Carl Anthony Evans · DirectorSince 2023
-
Faith L. Charles · DirectorSince 2022
-
Jeffry R. Keyes · DirectorSince 2023
-
Jerzy Gumulka · DirectorSince 2023
-
John M. Climaco · Director · Chief Executive OfficerSince 2023
-
Rami Levin · Director · CEO and PresidentSince 2026
Chief executives
Rami Levin
· CEO and President
Since January 2026
John M. Climaco
· Chief Executive Officer
Until January 2026
· Former
Board connections
3 of this board's directors also sit on 4 other boards.
- via Faith L. Charles
- via Bettina M. Cockroft
- via Faith L. Charles
- via John M. Climaco
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $34,009
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 18, 2026 | Faith L. Charles Director | Open-market purchase | +7,100 | $4.79 | $34,009 |
| Feb 1, 2024 | Jerzy Gumulka Director | Open-market purchase | +33,333 | $0.30 | $10,000 |
| Feb 1, 2024 | Carl Anthony Evans Director | Open-market purchase | +33,333 | $0.30 | $10,000 |
| Feb 1, 2024 | Downs Christopher Officer (Chief Financial Officer) | Open-market purchase | +66,666 | $0.30 | $20,000 |
| Feb 1, 2024 | John M. Climaco Director, Officer (Chief Executive Officer) | Open-market purchase | +166,666 | $0.30 | $50,000 |
| Aug 22, 2023 | Downs Christopher Officer (Chief Financial Officer) | Open-market purchase | +27,000 | $1.27 | $34,290 |
| Aug 16, 2023 | John M. Climaco Director, Officer (Chief Executive Officer) | Open-market purchase | +2,750 | $1.80 | $4,950 |
| Apr 28, 2023 | John M. Climaco Director, Officer (Chief Executive Officer) | Option exercise | +1,250 | — | — |
| Apr 28, 2023 | Downs Christopher Officer (Chief Financial Officer) | Option exercise | +521 | — | — |
| Apr 19, 2023 | Jerzy Gumulka Director | Open-market purchase | +2,500 | $1.70 | $4,250 |
| Apr 17, 2023 | Downs Christopher Officer (Chief Financial Officer) | Open-market purchase | +3,100 | $3.20 | $9,920 |
| Apr 12, 2023 | John M. Climaco Director, Officer (Chief Executive Officer) | Open-market purchase | +15,000 | $0.69 | $10,350 |
| Apr 10, 2023 | Jerzy Gumulka Director | Open-market purchase | +7,173 | $0.74 | $5,308 |
| Mar 28, 2023 | Priebe Waldemar 10% owner | Open-market sale | −10,000 | $1.04 | $10,400 |
| Mar 27, 2023 | Priebe Waldemar 10% owner | Open-market sale | −5,000 | $1.09 | $5,450 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.